Goldman Sachs’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-26,400
Closed -$4.75M 6948
2017
Q3
$4.75M Sell
26,400
-9,300
-26% -$1.3M ﹤0.01% 3197
2017
Q2
$3.7M Buy
35,700
+9,900
+38% +$808K ﹤0.01% 3313
2017
Q1
$2.02M Buy
25,800
+4,200
+19% +$260K ﹤0.01% 3734
2016
Q4
$969K Sell
21,600
-138,700
-87% -$6.8M ﹤0.01% 4482
2016
Q3
$8.95M Buy
160,300
+135,100
+536% +$7.53M ﹤0.01% 2547
2016
Q2
$1.26M Sell
25,200
-21,900
-46% -$1.08M ﹤0.01% 4000
2016
Q1
$2.16M Sell
47,100
-1,000
-2% -$48.4K ﹤0.01% 3401
2015
Q4
$2.96M Sell
48,100
-18,600
-28% -$1.31M ﹤0.01% 3292
2015
Q3
$3.71M Buy
66,700
+33,200
+99% +$2.09M ﹤0.01% 3161
2015
Q2
$2.04M Buy
33,500
+3,600
+12% +$205K ﹤0.01% 3808
2015
Q1
$1.73M Buy
+29,900
New +$2M ﹤0.01% 3938

Goldman Sachs's KITE Position: Q4 2017 in Review

Goldman Sachs sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 806,480 shares — an estimated $145M sold.

Goldman Sachs first reported a position in KITE in Q1 2015 and held it in 11 quarters. The position peaked at $145M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Goldman Sachs reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 806,480 Kite Pharma, Inc. shares in Q4 2017, an estimated $145M.
  • Goldman Sachs first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 11 quarters.
  • Goldman Sachs's Kite Pharma, Inc. position peaked at $145M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.